| Kyle Gross, | |
|
3 Richland Medical Park Dr Ste 510, Columbia, SC 29203-6854 | |
| (803) 360-6099 | |
| Not Available |
| Full Name | Kyle Gross |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 3 Richland Medical Park Dr Ste 510, Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033697362 | NPI | - | NPPES |
| NP5554 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LG0600X | Nurse Practitioner - Gerontology | 21917 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prisma Health Richland Hospital | Columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prisma Health Medical Group-midlands | 5991099707 | 865 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
454 Life Sciences, a Roche Company, and Fluidigm Corporation announced today that they have entered a worldwide co-promotional agreement for the companies' complementary amplicon sample preparation and high-throughput sequencing platforms.
An international team led by scientists at the University of Turku in Finland studied thermally-adapted fish populations to discover that the more biological functions a gene has, the less it responds to environmental change. "In addition to having important implications for climate change adaptation, these findings could radically change the way we study gene responses to any external stimulus like for example to drug treatments", the authors suggest.
According to the National Cancer Policy Board, it is estimated that by the year 2050 there will be more cancer survivors in the United States than those newly diagnosed with the disease.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over an approximately 18-month period. Poniard is not obligated to utilize any of the facility and remains free to enter into other financing transactions.
› Verified 8 days ago
| Entity Name | Prisma Health Medical Group-midlands |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275988321 PECOS PAC ID: 5991099707 Enrollment ID: O20160802001226 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
454 Life Sciences, a Roche Company, and Fluidigm Corporation announced today that they have entered a worldwide co-promotional agreement for the companies' complementary amplicon sample preparation and high-throughput sequencing platforms.
An international team led by scientists at the University of Turku in Finland studied thermally-adapted fish populations to discover that the more biological functions a gene has, the less it responds to environmental change. "In addition to having important implications for climate change adaptation, these findings could radically change the way we study gene responses to any external stimulus like for example to drug treatments", the authors suggest.
According to the National Cancer Policy Board, it is estimated that by the year 2050 there will be more cancer survivors in the United States than those newly diagnosed with the disease.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over an approximately 18-month period. Poniard is not obligated to utilize any of the facility and remains free to enter into other financing transactions.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kyle Gross, Po Box 743904, Atlanta, GA 30374-3904 Ph: (803) 296-7320 | Kyle Gross, 3 Richland Medical Park Dr Ste 510, Columbia, SC 29203-6854 Ph: (803) 360-6099 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
454 Life Sciences, a Roche Company, and Fluidigm Corporation announced today that they have entered a worldwide co-promotional agreement for the companies' complementary amplicon sample preparation and high-throughput sequencing platforms.
An international team led by scientists at the University of Turku in Finland studied thermally-adapted fish populations to discover that the more biological functions a gene has, the less it responds to environmental change. "In addition to having important implications for climate change adaptation, these findings could radically change the way we study gene responses to any external stimulus like for example to drug treatments", the authors suggest.
According to the National Cancer Policy Board, it is estimated that by the year 2050 there will be more cancer survivors in the United States than those newly diagnosed with the disease.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over an approximately 18-month period. Poniard is not obligated to utilize any of the facility and remains free to enter into other financing transactions.
› Verified 8 days ago
Mr. Joseph Crawford Iii, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 8 Richland Medical Park Dr Ste 300, Columbia, SC 29203 Phone: 803-256-6511 | |
Richard Hall Iii, APRN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Richland Medical Park Dr Ste 100, Columbia, SC 29203 Phone: 803-434-6095 Fax: 803-758-0120 | |
Latonya Brailsford, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4605 Monticello Rd Ste 2, Columbia, SC 29203 Phone: 803-753-5590 Fax: 803-753-5592 | |
Laketa D Riley, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 111 Doctor Cir, Columbia, SC 29203 Phone: 800-491-0909 | |
Jenny O'neill, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 200 Arbor Lake Dr, Suite 120, Columbia, SC 29223 Phone: 803-457-8125 Fax: 803-457-8129 | |
Sarah Elizabeth Wilson, PNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 9 Richland Medical Park Dr Ste 420, Columbia, SC 29203 Phone: 803-434-3950 Fax: 803-434-3496 | |
Miss Karen Mccain, NURSE PRACTITONER Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 111 Doctor Cir, Columbia, SC 29203 Phone: 800-491-0909 |